Clinical Trial Update: A Study to Investigate the Safety, Tolerability and Pharmacokinetics of SUVN-G3031 in Healthy Subjects [Phase 1]

View source ↗

Summary

Phase 1 study assessing safety, tolerability, and pharmacokinetics of SUVN-G3031 in healthy subjects has completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cognitive Disorders

Drugs mentioned

• SUVN-G3031

Snippet

Sponsor: Suven Life Sciences Limited | Conditions: Cognitive Disorders | Phase 1 | Status: COMPLETED